JP2024544566A5 - - Google Patents

Info

Publication number
JP2024544566A5
JP2024544566A5 JP2024528594A JP2024528594A JP2024544566A5 JP 2024544566 A5 JP2024544566 A5 JP 2024544566A5 JP 2024528594 A JP2024528594 A JP 2024528594A JP 2024528594 A JP2024528594 A JP 2024528594A JP 2024544566 A5 JP2024544566 A5 JP 2024544566A5
Authority
JP
Japan
Prior art keywords
lentiviral vector
acid sequence
nucleic acid
antigen
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024528594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/081839 external-priority patent/WO2023084094A1/en
Publication of JP2024544566A publication Critical patent/JP2024544566A/ja
Publication of JP2024544566A5 publication Critical patent/JP2024544566A5/ja
Pending legal-status Critical Current

Links

JP2024528594A 2021-11-15 2022-11-14 ヒトパピローマウイルス(hpv)抗原の発現の為のレンチウイルスベクター、並びにhpv誘発癌の処置におけるその実施 Pending JP2024544566A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21306581.6 2021-11-15
EP21306581 2021-11-15
US202163279945P 2021-11-16 2021-11-16
US63/279,945 2021-11-16
EP22306119 2022-07-27
EP22306119.3 2022-07-27
PCT/EP2022/081839 WO2023084094A1 (en) 2021-11-15 2022-11-14 Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers

Publications (2)

Publication Number Publication Date
JP2024544566A JP2024544566A (ja) 2024-12-03
JP2024544566A5 true JP2024544566A5 (cg-RX-API-DMAC7.html) 2025-10-14

Family

ID=84536137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528594A Pending JP2024544566A (ja) 2021-11-15 2022-11-14 ヒトパピローマウイルス(hpv)抗原の発現の為のレンチウイルスベクター、並びにhpv誘発癌の処置におけるその実施

Country Status (7)

Country Link
US (1) US20240415951A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433081A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024544566A (cg-RX-API-DMAC7.html)
KR (1) KR20240124919A (cg-RX-API-DMAC7.html)
AU (1) AU2022386715A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238020A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023084094A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318598A (en) * 2022-07-27 2025-03-01 Theravectys Lentiviral vectors for the expression of human papillomavirus (HPV) antigens and their application in the treatment of HPV-induced cancer
CN116286982B (zh) * 2022-09-09 2024-01-30 广州凯普医药科技有限公司 一种hpv基因分型检测阳性参考品及其制备方法和应用
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2337429T3 (es) 1999-10-11 2010-04-23 Institut Pasteur Vectores lentivirales para la preparacion de composiciones inmunoterapeuticas.
ES2708856T3 (es) * 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
CA2956385A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

Similar Documents

Publication Publication Date Title
US8389275B2 (en) Fusion proteins of HIV regulatory/accessory proteins
JP6655051B2 (ja) 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
JP2019526580A5 (cg-RX-API-DMAC7.html)
US20130302367A1 (en) Virus vector for prime/boost vaccines, which comprises vaccinia virus vector and sendai virus vector
JP2010535495A5 (cg-RX-API-DMAC7.html)
CN102046785A (zh) 基于慢病毒的免疫原性载体
US20190151437A1 (en) Combination prime: boost therapy
Malkevitch et al. A call for replicating vector prime-protein boost strategies in HIV vaccine design
CN104039968B (zh) 非b亚型gag蛋白在慢病毒包装中的应用
JP2021506300A (ja) B型肝炎ウイルス(hbv)に対する免疫応答を誘導するための方法および組成物
Xu et al. Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques
Tallet et al. Sequence variations in the amino-and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies
RU2697781C2 (ru) Вспомогательный плазмидный лентивирусный экспрессионный вектор для получения высоких титров vpx-содержащих лентивирусных частиц, обеспечивающий эффективное заражение моноцитов и дендритных клеток человека
JP2010168288A (ja) 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
during Assembly Polyprotein Processing
Letvin et al. A Human T-Cell Leukemia Virus Type
CN118354790A (zh) 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发癌症中的应用
McKenna Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins
Cohen ANIMAL VIRUSES
Ertl et al. Induction of CD8+ T Cells to an HIV-1
JP2010248179A (ja) 医薬組成物